Despite advances in antiretroviral therapy that have revolutionized HIV disease
management, effective control of the HIV infection pandemic remains elusive. Beyond the …

Analysis of HIV drug resistance has identified sites on HIV target genes that convey
resistance to particular classes of agents. These data may be especially important in …

Most of the current knowledge on antiretroviral (ARV) drug development and resistance is
based on the study of subtype B of HIV-1, which only accounts for 10% of the worldwide HIV …

The vast majority of reports on drug resistance deal with subtype B infections in developed
countries, and this is largely due to historical delays in access to antiretroviral therapy (ART) …

We demonstrate that at least three different promoter variant strains of HIV-1 subtype C have
been gradually expanding and replacing the standard subtype C viruses in India, and …

Objective: To investigate the origin and to reconstruct the onset date of the HIV-1 subtype C
epidemic in Brazil. Design: Three independent datasets of subtype C sequences isolated …

Ninety percent of HIV-1-infected people worldwide harbour non-subtype B variants of HIV-1.
Yet knowledge of resistance mutations in non-B HIV-1 and their clinical relevance is limited …

The HIV-1 has evolved swiftly and the scenario of HIV-1 genetic diversity is constantly
changing. In South America, recombinant forms of subtypes B, F1, and BF1 have historically …

The genetic diversity of HIV-1 has required its classification into types and subtypes. There is
controversy as to how and to what extent genetic diversity may affect the emergence of …

Subtype C is the most prevalent clade of human immunodeficiency virus type 1 (HIV-1)
worldwide. The reasons for this are poorly understood. Here, we demonstrate that a …